• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用基础呼吸困难指数(BDI)和过渡呼吸困难指数(TDI)评估结节病患者的呼吸困难。

Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI).

机构信息

Division of Pulmonary Critical Care and Sleep Medicine, 3E-149E Brody Medical Sciences Building, 600 Moye Blvd, Mail Stop 628, Brody School of Medicine, East Carolina University, Greenville, NC, 27834-4354, USA.

Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York, 12208, USA.

出版信息

Respir Med. 2022 Jan;191:106436. doi: 10.1016/j.rmed.2021.106436. Epub 2021 May 4.

DOI:10.1016/j.rmed.2021.106436
PMID:33992496
Abstract

INTRODUCTION

The Borg and Modified Medical Research Council (mMRC) dyspnea scales have been used to evaluate dyspnea in sarcoidosis. The Baseline Dyspnea Index (BDI) and Transitional Dyspnea Index (TDI) are useful for the assessment of dyspnea in COPD. It is not known if the BDI-TDI accurately assesses dyspnea in sarcoidosis patients.

METHODS

Data was analyzed from the Registry for Advanced Sarcoidosis (ReAS), a multi-national database enrolling patients with advanced sarcoidosis and a comparison group of sarcoidosis patients with non-advanced disease. At baseline, patients completed a BDI questionnaire along with spirometry, 6-min walk distance (6MWD), mMRC, Borg score, fatigue assessment score (FAS) and HRQoL assessments using Kings Sarcoidosis Questionnaire (KSQ) and St Georges Respiratory Questionnaire (SGRQ). At 12-months, patients with advanced disease completed a TDI questionnaire along with the other measures. Correlations between BDI and baseline variables, and between TDI and changes in baseline variables were evaluated.

RESULTS

There was significant correlation (p < 0.001 for all) between BDI and baseline 6MWD (rho = 0.336), FVC% (rho = 0.387), FEV1% (rho = 0.285), DLCO% (rho = 0.355), mMRC (rho = -0.721), Borg score (rho = -0.389), FAS (rho = -0.669), SGRQ (rho = -0.785), and KSQ (rho = 0.318 to 0.724). At follow-up, TDI correlated with BDI, but not with changes in pulmonary function or other dyspnea measures.

CONCLUSION

BDI scores correlated with pulmonary function, 6MWD, and other dyspnea measures. TDI scores did not correlate with changes in pulmonary function or other dyspnea measures. BDI may be a useful independent measure of dyspnea in sarcoidosis patients. The role of TDI needs further evaluation in longitudinal studies associated with changes in clinical parameters.

摘要

引言

博尔格(Borg)和改良版医学研究委员会(mMRC)呼吸困难量表已被用于评估结节病患者的呼吸困难。基线呼吸困难指数(BDI)和过渡性呼吸困难指数(TDI)可用于评估 COPD 患者的呼吸困难。目前尚不清楚 BDI-TDI 是否能准确评估结节病患者的呼吸困难。

方法

对来自多中心注册研究(ReAS)的数据进行分析,该注册研究纳入了患有晚期结节病的患者和一组非晚期疾病的结节病患者作为对照组。在基线时,患者完成了 BDI 问卷以及肺量计检查、6 分钟步行距离(6MWD)、mMRC、Borg 评分、疲劳评估评分(FAS)和使用 King’s 结节病问卷(KSQ)和圣乔治呼吸问卷(SGRQ)进行的 HRQoL 评估。在 12 个月时,患有晚期疾病的患者完成了 TDI 问卷和其他评估。评估了 BDI 与基线变量之间的相关性,以及 TDI 与基线变量变化之间的相关性。

结果

BDI 与基线 6MWD(rho=0.336,p<0.001)、FVC%(rho=0.387,p<0.001)、FEV1%(rho=0.285,p<0.001)、DLCO%(rho=0.355,p<0.001)、mMRC(rho=-0.721,p<0.001)、Borg 评分(rho=-0.389,p<0.001)、FAS(rho=-0.669,p<0.001)、SGRQ(rho=-0.785,p<0.001)和 KSQ(rho=0.318-0.724,p<0.001)均显著相关(p<0.001)。在随访时,TDI 与 BDI 相关,但与肺功能或其他呼吸困难测量指标的变化无关。

结论

BDI 评分与肺功能、6MWD 和其他呼吸困难测量指标相关。TDI 评分与肺功能或其他呼吸困难测量指标的变化无关。BDI 可能是评估结节病患者呼吸困难的一种有用的独立指标。TDI 的作用需要在与临床参数变化相关的纵向研究中进一步评估。

相似文献

1
Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI).使用基础呼吸困难指数(BDI)和过渡呼吸困难指数(TDI)评估结节病患者的呼吸困难。
Respir Med. 2022 Jan;191:106436. doi: 10.1016/j.rmed.2021.106436. Epub 2021 May 4.
2
[Comparison of different evaluation systems for assessing disease severity and treatment efficacy in patients with chronic obstructive pulmonary disease].[慢性阻塞性肺疾病患者疾病严重程度及治疗疗效评估的不同评估系统比较]
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Jul 20;41(7):1119-1124. doi: 10.12122/j.issn.1673-4254.2021.07.23.
3
Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease.改良医学研究委员会量表与基线呼吸困难指数用于评估慢性阻塞性肺疾病中的呼吸困难
Int J Chron Obstruct Pulmon Dis. 2015 Aug 18;10:1663-72. doi: 10.2147/COPD.S82408. eCollection 2015.
4
Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD.结果测量在检测慢性阻塞性肺疾病患者肺康复中具有临床意义变化方面的效能。
Chest. 2002 Apr;121(4):1092-8. doi: 10.1378/chest.121.4.1092.
5
Dyspnea in COPD: beyond the modified Medical Research Council scale.COPD 患者的呼吸困难:不只是改良版英国医学研究理事会呼吸困难量表。
J Bras Pneumol. 2010 Sep-Oct;36(5):571-8. doi: 10.1590/s1806-37132010000500008.
6
[Validation study of the BDI/TDI scores in chronic obstructive pulmonary disease].[慢性阻塞性肺疾病中BDI/TDI评分的验证研究]
Rev Mal Respir. 2009 Sep;26(7):735-43. doi: 10.1016/s0761-8425(09)72424-6.
7
A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease.一项对四项随机临床试验的荟萃分析,以证实日常活动气短(SOBDA)问卷在慢性阻塞性肺疾病中的可靠性和反应性。
Health Qual Life Outcomes. 2015 Oct 31;13:177. doi: 10.1186/s12955-015-0369-3.
8
[Ways to quantify dyspnea severity. Part I. Baseline Dyspnea Index (BDI), Transition Dyspnea Index (TDI)].量化呼吸困难严重程度的方法。第一部分。基线呼吸困难指数(BDI)、过渡性呼吸困难指数(TDI)。
Pneumologia. 2006 Apr-Jun;55(2):58-63.
9
[Role of dyspnea in quality of life of the patient with chronic obstructive pulmonary disease].[呼吸困难在慢性阻塞性肺疾病患者生活质量中的作用]
Arch Bronconeumol. 1999 Jun;35(6):261-6.
10
Evaluation of three scales of dyspnea in chronic obstructive pulmonary disease.评估三种慢性阻塞性肺疾病呼吸困难量表。
Ann Thorac Med. 2009 Jul;4(3):128-32. doi: 10.4103/1817-1737.53351.

引用本文的文献

1
The Symptoms of Pulmonary Sarcoidosis.肺结节病的症状。
J Clin Med. 2023 Sep 20;12(18):6088. doi: 10.3390/jcm12186088.
2
Therapeutic Approaches for the Treatment of Interstitial Lung Disease: An Exploratory Review on Molecular Mechanisms.治疗间质性肺病的方法:对分子机制的探索性综述。
Mini Rev Med Chem. 2024;24(6):618-633. doi: 10.2174/1389557523666230816090112.
3
Novel biomarkers for the assessment of disease activity in patients with sarcoidosis: a case-control study.用于评估结节病患者疾病活动度的新型生物标志物:一项病例对照研究。
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Jun 29;40(2):e2023017. doi: 10.36141/svdld.v40i2.14327.
4
Health-related quality of life in cardiac sarcoidosis: a systematic review.心脏结节病患者的健康相关生活质量:一项系统综述。
Eur Heart J Open. 2023 Feb 18;3(2):oead009. doi: 10.1093/ehjopen/oead009. eCollection 2023 Mar.
5
Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches.结节病:治疗药物试验及新治疗方法的最新进展
Front Med (Lausanne). 2022 Oct 12;9:991783. doi: 10.3389/fmed.2022.991783. eCollection 2022.
6
Shortness of Breath on Day 1 After Surgery Alerting the Presence of Early Respiratory Complications After Surgery in Lung Cancer Patients.术后第1天出现呼吸急促提示肺癌患者术后存在早期呼吸并发症。
Patient Prefer Adherence. 2022 Mar 19;16:709-722. doi: 10.2147/PPA.S348633. eCollection 2022.
7
The Chameleon Behavior of Sarcoidosis.结节病的变色龙行为
J Clin Med. 2021 Jun 24;10(13):2780. doi: 10.3390/jcm10132780.